Abstract
After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinical data have come from the use of RIT in the treatment of lymphoma and haematological malignancies and it would now appear highly likely that RIT will play a major role in the treatment strategies for these diseases. For the solid tumours there has also been considerable progress with RIT and mAbs have become a component of treatment protocols for breast cancer. This review highlights the important recent clinical progress that has been made with clinical RIT and provides some new insights into the important mechanisms of action of RIT in haematological malignancies.
Keywords: Target radiotherapy, monoclonal antibodies (mAbs), Radioimmunotherpy (RIT), Haematological malignancies, ADCC, Antibodies, Tumour nodules, HAMA response, Immunosuppression, Cyclosporin, Deoxysperualin, The Radioisotope, Radioimmunoglobulin, Normal tissue toxicity, Dosimetry, MIRD, Non myeloablative therapy in lymphoma, CD20 antibodies, Phase II pivotal, Complete response, Maximum Tolerated Dose, Immunoglobulin idiotype, IDEC Y2B8, Solid tumours
Current Pharmaceutical Design
Title: Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy
Volume: 6 Issue: 14
Author(s): Timothy M. Illidge and Susannah Brock
Affiliation:
Keywords: Target radiotherapy, monoclonal antibodies (mAbs), Radioimmunotherpy (RIT), Haematological malignancies, ADCC, Antibodies, Tumour nodules, HAMA response, Immunosuppression, Cyclosporin, Deoxysperualin, The Radioisotope, Radioimmunoglobulin, Normal tissue toxicity, Dosimetry, MIRD, Non myeloablative therapy in lymphoma, CD20 antibodies, Phase II pivotal, Complete response, Maximum Tolerated Dose, Immunoglobulin idiotype, IDEC Y2B8, Solid tumours
Abstract: After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinical data have come from the use of RIT in the treatment of lymphoma and haematological malignancies and it would now appear highly likely that RIT will play a major role in the treatment strategies for these diseases. For the solid tumours there has also been considerable progress with RIT and mAbs have become a component of treatment protocols for breast cancer. This review highlights the important recent clinical progress that has been made with clinical RIT and provides some new insights into the important mechanisms of action of RIT in haematological malignancies.
Export Options
About this article
Cite this article as:
Illidge M. Timothy and Brock Susannah, Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy, Current Pharmaceutical Design 2000; 6 (14) . https://dx.doi.org/10.2174/1381612003399257
DOI https://dx.doi.org/10.2174/1381612003399257 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Chinese Medicine: A Novel Therapeutic Option for Pancreatic Cancer
Current Signal Transduction Therapy Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Ligustrazine-Based Synthetic Compounds for their Antiproliferative Effects
Medicinal Chemistry Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design
Current Medicinal Chemistry Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on Biotechnology The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Antiproliferative and Antioxidant Potential of Leaf and Leaf Derived Callus Extracts of Aerva lanata (L.) Juss. Ex Schult. Against Human Breast Cancer (MCF-7) Cell Lines
The Natural Products Journal Modified Nucleosides That Can Be Incorporated into DNA Enzymatically or in Live Cells
Current Organic Chemistry Endogeneous Remyelination: Findings in Human Studies
CNS & Neurological Disorders - Drug Targets Imaging Studies in Hypercalcemia
Current Medicinal Chemistry